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Despite the potential to improve patient outcomes, the application of pharmacogenomics
(PGx) is yet to be routine. A growing number of PGx implementers are leaning toward using
combinatorial PGx (CPGx) tests (i.e., multigene tests) that are reusable over patients’ lifetimes.
However, selecting a single best available CPGx test is challenging owing to many patientand population-specific factors, including variant frequency differences across ethnic groups.
The primary objective of this study was to evaluate the detection rate of currently available
CPGx tests based on the cytochrome P450 (CYP) gene variants they target. The detection
rate was defined as the percentage of a given population with an “altered metabolizer”
genotype predicted phenotype, where a CPGx test targeted both gene variants a prospective
diplotypes. A potential genotype predicted phenotype was considered an altered metabolizer
when it resulted in medication therapy modification based on Clinical Pharmacogenetics
Implementation Consortium (CPIC) guidelines. Targeted variant CPGx tests found in the
Genetic Testing Registry (GTR), gene selection information, and diplotype frequency data
from the Pharmacogenomics Knowledge Base (PharmGKB) were used to determine the
detection rate of each CPGx test. Our results indicated that the detection rate of CPGx tests
covering CYP2C19, CYP2C9, CYP2D6, and CYP2B6 show significant variation across
ethnic groups. Specifically, the Sub-Saharan Africans have 63.9% and 77.9% average
detection rates for CYP2B6 and CYP2C19 assays analyzed, respectively. In addition, East
Asians (EAs) have an average detection rate of 55.1% for CYP2C9 assays. Therefore, the
patient’s ethnic background should be carefully considered in selecting CPGx tests.
Keywords: pharmacogenomics, pharmacogenomic tests, variant selection, detection rate, cytochrome P450
enzymes

INTRODUCTION
Drug-related morbidity and mortality owing to unoptimized medication therapy are estimated
to cost $528.4 billion annually in the United States alone (Watanabe et al., 2018). Pharmacogenomics
(PGx) – the study of the role of an individual’s genetic makeup in drug response – has the
potential to reduce adverse reactions to medications and lower medical costs by individualizing
1
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treatments based on genetic makeup. In a study of Medicare
and Medicaid patients examining over 70 million patient records,
over half of the patient population received at least one drug
with PGx implications (Samwald et al., 2016). Studies comparing
PGx guided therapies vs. non-PGx guided therapies in psychiatric
patients show both improved therapy outcomes and significant
cost savings (Hornberger et al., 2015; Tanner et al., 2019).
Clinical PGx practice has the potential to be relevant to a
large patient population, bring cost savings, and improve
therapy outcomes.
Critical to PGx implementation is the availability of genetic
test results having relevant genes to guide therapy decisions.
Reactionary approaches to PGx practice, meaning individual
genes are tested when there is a suspected need, is inefficient
with respect to cost and time. As clinical decision support
systems grow, preemptive PGx testing approaches are being
utilized, allowing genotyping results to be available prior to
prescribing decisions and in the planning of therapy
(Dunnenberger et al., 2015). Combinatorial PGx tests (CPGx)
are critical to the development of these programs because they
offer genotyping results of several different genes simultaneously.
While utilizing CPGx tests preemptively helps overcome barriers
to PGx implementation, it is important to ensure the genotyping
results they provide are reliable. If CPGx tests utilized
preemptively have limitations, they can cause sub-optimal
outcomes for subsequent therapeutic decisions.
Cytochrome P450 (CYP) enzyme genotypes are relevant to
PGx practice for a variety of reasons. CYP enzymes play a
role in the metabolism of over 90% of available prescription
medications (Lynch and Price, 2007; McDonnell and Dang,
2013). In addition to their critical role in drug metabolism,
the prevalence of genetic polymorphisms of CYP enzymes is
well documented in diverse patient populations. In a study of
nearly 10,000 patients screened for common CYP enzyme
variants, 91% of them had at least one variant linked to changed
metabolic status (Van Driest et al., 2014). CYP Enzyme genotyping
plays a central role in PGx practice for these reasons. Given
this, the success of a preemptive PGx testing program with
CPGx tests can be greatly influenced by the extent CYP enzyme
genotypes are accurately characterized.
Gene variant selection of CPGx tests is an essential factor
to consider that can influence therapeutic decisions (Petry
et al., 2021). CPGx test performance can vary because laboratories
providing PGx tests use targeted genotyping technologies to
screen for specific variants with well-characterized drug-gene
interactions (Guo et al., 2019). Currently, all target variant
CPGx tests that do not find putative variants included in the
test report the gene as a normal (*1) variant by default (Mukerjee
et al., 2018). In a study of CYP2C9 genotype-guided warfarin
dosing vs. standard clinical dosing in 2013, African American
patients were in the therapeutic range significantly less with
genotype-guided doses (Kimmel et al., 2013). Subsequent studies
incorporating more relevant variants showed significantly
improved outcomes (Limdi et al., 2015). Determining appropriate
CPGx tests to be used for each patient based on relevant gene
variants is a potential barrier providers face in implementing
PGx testing services.
Frontiers in Genetics | www.frontiersin.org

One of the challenges in determining an appropriate CPGx
test is the lack of publicly available information describing them.
In a study of direct-to-consumer genetic tests in 2016, less than
one-third of tests identified had specific gene variant selection
information available (Hall et al., 2017). The National Institutes
of Health (NIH) created the Genetic Testing Registry (GTR) in
2010 to collect genetic test information and to enhance their
availability, validity, and usefulness (Rubinstein et al., 2013).
Information about the tests is voluntarily reported by the
commercial clinical laboratories who developed them and is
updated regularly. The GTR is considered one of the most valuable
genetic testing repositories and is often cited in PGx guidelines.
There are additional resources that support PGx
implementation. The Clinical Pharmacogenomics Implementation
Consortium (CPIC) helps by creating, curating, and posting
freely available, peer-reviewed, evidence-based, updatable, and
detailed gene/drug clinical practice guidelines (Relling and
Klein, 2011). The Pharmacogenomics Knowledge Base
(PharmGKB) is another resource that curates and disseminates
knowledge about clinically actionable gene-drug associations,
genotype-phenotype relationships, and gene frequency data
(Whirl-Carrillo et al., 2012). Finally, specifically for variant
selection guidance, the Association for Molecular Pathology
(AMP) has established a two-tier evidence-based recommendation
system to help laboratory professionals select appropriate gene
variants in genotyping assays for CYP2C9 and CYP2C19 (Pratt
et al., 2018, 2019). These resources can aid clinicians to know
what variants would be appropriate for their patients in
CPGx tests.
In our study, we specifically evaluate CPGx tests and their
variant selection practices with respect to CYP enzymes. This
is due to the critical role CPGx tests and CYP enzymes play
in the implementation of preemptive CPGx testing programs.
We leverage valuable resources (GTR, CPIC, PharmGKB, and
AMP) to perform our evaluation of the current landscape of
detection rates of available CPGx tests based on known variant
frequencies across various ethnic populations. A list of potential
CPGx tests were identified utilizing the GTR, which was
subsequently filtered to only include CYP relevant tests. For
subsequent analysis, published CPIC guidelines were utilized
to identify CYP enzyme phenotypes of interest. These in
combination with PharmGKB gene frequency data allowed us
to determine the extent genotype predicted phenotypes of
interest occur in diverse populations and how well CPGx tests
identify them. In our evaluation, gene coverage percentages
were determined and the detection rate of CPGx tests were
calculated covering five CYP enzymes across various
ethnic groups.

MATERIALS AND METHODS
Identification of PGx Tests

The GTR was used to identify PGx tests from 02/23/2021 to
02/26/2021. As keywords, “pharmacogenetic” or “pharmacogenetics”
or “pharmacogenomics” or “pharmacogenomic” were used for
the search. The resulting PGx test list was filtered based on the
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following inclusion criteria: assays that used “targeted variant
analysis” as their test methodology, CPGx tests including at least
two genes, and publicly available gene variant selection information
(Supplementary Figure 1). Exclusion criteria for potential CPGx
tests included assays using alternative sequencing techniques
(whole genome or exome sequencing), assays only including one
gene, and CPGx tests without publicly available variant selection
information. Gene and variant coverage for the CYP enzymes,
specifically, CYP2B6, CYP2D6, CYP2C9, CYP2C19, and CYP3A5,
were investigated due to their well-studied gene frequencies and
role in PGx practice. Variants considered for analysis of gene
selection, gene coverage percentage, and detection rate were those
included in PharmGKB gene frequency tables (See
Supplementary Table 1 for detailed list).

enzyme sub-group (Table 1). Even though, predicted phenotype
does not guarantee adverse drug reactions or suboptimal
outcomes, in a pre-emptive approach the resulting predicted
phenotypes would influence future therapy decisions. Thus,
for our study, we rely on these genotype-predicted phenotypes
to define “altered metabolizers.”
Population altered metabolizer frequency is the sum of all
altered metabolizer diplotype frequencies for each ethnic group.
Detectable altered metabolizer frequency represents the total
frequency of altered metabolizers, where a given CPGx test contains
both gene variants within its diplotype (detectable diplotypes).
Detection rate is the proportion of individuals with altered
metabolizing genotype predicted phenotypes that have detectable
diplotypes. Therefore, it is calculated by dividing the detectable
altered metabolizer frequency by the population altered metabolizer
frequency (Eq. 2). Each ethnic group represented in gene frequency
tables has a detection rate value calculated for each CPGx test.

Calculation of CPGx Test Coverage
Percentage

To illustrate the extent of the number of variants included in
PGx tests relative to the number of known variants, a variant
coverage percentage was calculated for each CPGx test. Gene
coverage percentage is the total number of variants targeted
by a CPGx test divided by the total known variants (Eq. 1).
Total known variants were the number of listed variants within
PharmGKB gene frequency tables.
CPGx test coverage percentage =

Number of variants targeted
Total number of known variants

Detection Rate =

Equation 2: Calculation of detection rate. Altered metabolizer
phenotypes are defined as genotype predicted phenotypes
resulting in an alteration of medication therapy. Detectable
altered metabolizer frequency is the sum of all altered metabolizer
diplotypes frequencies, where both gene variants are included
in the CPGx test. Population altered metabolizer frequency is
the sum of all altered metabolizer diplotypes frequencies.

x 100

Equation 1: Calculation of CPGx test coverage percentage.
The number of variants targeted was found by identifying
which variants each CPGx test selected from a search using
the GTR and other resources. The total number of chosen
variants were then summed, in which the total number of
known variants was the number of listed variants within the
PharmGKB gene frequency tables.

TABLE 1 | Genotype-predicted phenotypes for each CYP enzyme that cause
alteration of medication therapy (altered metabolizing status) based on Clinical
Pharmacogenomics Implementation Consortium (CPIC) guidelines.
CYP enzyme

Genotype-predicted
phenotypes
considered an altered
metabolizer status

CPIC Guidelines
Referenced

CYP2B6

Intermediate and poor
metabolizers

CYP2C19

Ultra-rapid, rapid, likely
intermediate,
intermediate, likely poor,
and poor metabolizers

Efavirenz and efavirenzContaining Antiretroviral
Therapy
Proton Pump Inhibitors

Calculation of Detection Rate

Diplotype to phenotype translation and diplotype frequencies
were obtained from the PharmGKB database for CYP2B6,
CYP2D6, CYP2C9, CYP2C19, and CYP3A5. These reported
frequencies include nine different ethnic groups. The diplotypes
included in PharmGKB lists are based on the Pharmacogene
Variation (PharmVar) database and the resulting diplotypes
from their listed core variants (Gaedigk et al., 2018). These
resources, combined with PGx test information from the GTR,
were used to calculate the detection rate of CPGx tests in the
different ethnic groups.
Potential diplotypes for CYP enzyme subclasses were filtered
to only include those that predict “altered metabolizer”
phenotypes. A genotype-predicted phenotype is considered an
“altered metabolizer” when it results in a required alteration
of medication therapy to dosage or medication choice according
to published CPIC guidelines (Birdwell et al., 2015; Hicks et al.,
2015; Bell et al., 2017; Hicks et al., 2017; Desta et al., 2019;
Theken et al., 2020; Crews et al., 2021; Karnes et al., 2021;
Lima et al., 2021). Genotype-predicted phenotypes leading to
potential altered metabolizer status are unique to each CYP

Frontiers in Genetics | www.frontiersin.org

Detectable altered metabolizer frequency
x 100
Population altered metabolizer frequency

CYP2C9

CYP2D6

Activity scores less than
2
Activity scores less than
1.25 and greater than
2.25

Selective Serotonin
Reuptake Inhibitors
Tricyclic Antidepressants
Clopidogrel
Phenytoin
Fosphenytoin
NSAIDs
Opioids
Selective Serotonin
Reuptake Inhibitors
Tricyclic Antidepressants
Atomoxetine
Ondansetron

CYP3A5

3

Intermediate and
extensive metabolizers

Tropisetron
Tacrolimus
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Association for Molecular Pathology Tier 1 and Tier 2
recommendations were evaluated for CYP2C9 and CYP2C19.
Detection rate was calculated for each tier in the same way
it was calculated for prospective CPGx tests. These results
show the extent these recommended tiers are representative
of diverse ethnic groups and allow for comparison of current
PGx tests against AMP recommendations. Since only publicly
available datasets were used and no animal study was
conducted, this study did not require IRB or IACUC approval.
All analysis codes are available at https://github.com/sayer108/
CPGx_test_evaluation.

had an average detection rate of 70% or higher. AMP Tier 1
and Tier 2 recommendations also had very low detection rates
for the EA population, 51 and 55%, respectively. Both tiers had
detection rates of 95% or higher for all other ethnic groups
(Figure 3A; Supplementary Tables 1, 3, and 8). The highest
performing CPGx test among East Asians was the RPRD assay,
with a detection rate of 92%. However, for other ethnic groups
like Sub-Saharan African (SSA) and African-American AfroCaribbean (AAAC) populations the CPGx test with the highest
detection rate was the Admera assay with a detection rate of
99% (Supplementary Table 8). Similarly, the PharmGKB lists
137 potential variants for CYP2D6 and tests analyzed have gene
coverage percentage ranging from 15 to 54%. Average detection
rates for all CPGx tests with respect to all ethnic groups ranged
from 70 to 90%, with no obvious outliers (Figure 3B;
Supplementary Tables 1 and 4). All ethnic groups had the
highest detection rate with the RPRD assay except for East Asian
populations, where the OneOme assay had the highest detection
rate. PharmGKB lists 32 potential variants for CYP2C19 with
gene coverage percentages ranging from 5.7 to 75%. The detection
rate for the SSA and AAAC populations was lower than the
rest of the ethnic groups, 77, and 85%, respectively. The rest
of the ethnic groups had average detection rates of 95% or
higher for all CPGx tests. RPRD had the highest detection rate
for AAAC and SSA populations at 100%. Many of the Ethnic
groups had 100% detection rates with several different assays
studied. AMP recommended Tier 1 and Tier 2 variants had
detection rate values of 95% or higher for all ethnic groups
except the SSA and AAAC populations. Tier 1 had a detection
rate value of 75% for the SSA population, much lower than
Tier 2 at 93% (Figure 3C; Supplementary Tables 1, 5, and 8).
The PharmGKB lists 38 potential variants for CYP2B6; gene
coverage percentage ranged from 7 to 26.3%. The SSA population
had an average detection rate of 63.9% for all CPGx tests, the
lowest compared to all ethnic groups. The rest of the groups
had average detection rates greater than 70% for all CPGx tests
(Figure 3D; Supplementary Tables 1 and 6). The RPRD assay
performed best for the SSA population with a detection rate of
100%. Results for CYP3A5 showed a 100% detection rate for
all CPGx tests (Supplementary Tables 2, 7, and 8).

RESULTS
Genetic Testing Registry Search Results

A search of the GTR showed 178 potential PGx tests, 56 of
them being CPGx tests (Figure 1A). Gene selection information
was publicly available for 25% of CPGx tests, only 14 of 56
of them. CYP2C9, CYP2C19, and CYP2D6 were selected by
11 CPGx tests; only six CPGx tests covered CYP2B6. The
most commonly selected gene targets in CPGx tests were CYP
enzymes, with CYP2D6 and CYP2C19 being selected by 50
different tests (Figure 1B; Diagnostics R, 2021; Genetics C,
2021; Genetics H, 2021; Genomics A, 2021; Health A, 2021a,b;
Incorporated CH, 2021; Indiana University School of Medicine
DoDG-PL, 2021; Invitae, 2021; Laboratories KD, 2021; Lineagen,
2021; OneOme, 2021; Services PML, 2021).

Prevalence of Altered Metabolizing CYP
Phenotypes

Altered metabolizer genotype predicted phenotypes make up
a significant proportion of population for all ethnic groups
analyzed within each CYP enzyme subclass (Figure 2). The
average altered metabolizer frequencies (range) across ethnic
groups for each CYP enzyme subclass were CYP2B6 67%
(50–87%), CYP2C19 62% (37–96%), CYP2C9 26% (9–40%),
CYP2D6 23% (32–57%), and CYP3A5 44% (14–73%).

Coverage Percentage and Detection Rate
of Pharmacogenomic Tests

DISCUSSION

The detection rate of PGx tests was calculated for 14 CPGx
tests that covered one or more of the following CYPs: CYP2B6,
CYP2C9, CYP2C19, CYP2D6, and CYP3A5. The detection rate
of CPGx tests varied significantly, with values ranging from 24
to 100%. The average overall detection rate and range of values
of detection rate of the CPGx tests for all ethnic groups within
each CYP enzyme sub-group were CYP2B6 (77.6%, 43–100%),
CYP2C9 (88.4%, 24–100%), CYP2C19 (92.3%, 32–100%),
CYP2D6 (81.4, 56–100%), and CYP3A5 (100%, 100–100%;
Supplementary Tables 2–8; Supplementary Figure 2).
The PharmGKB lists 61 potential variants for CYP2C9; gene
coverage percentage ranged from 4.9 to 23% for CPGx tests
covering CYP2C9. The detection rate for the East Asian (EA)
population was lower than the rest of the ethnic groups, with
an average of 55% across CPGx tests. All other ethnic groups

Frontiers in Genetics | www.frontiersin.org

In this study, the ranges of detection rates were evaluated for
currently available CPGx tests to demonstrate the variability
that can occur depending on ethnic background and PGx test
selection. Our results showed some ethnic groups clearly have
higher and more consistent detection rate scores across CYP
enzymes compared to others. This demonstrates that variant
selection for the chosen assay can favor some populations
more than others. Additionally, even patients of the same ethnic
background can receive CPGx tests with drastically different
detection rates due to variant selection.
The calculated detection rate of CPGx tests reflected that
certain ethnic groups had diminished detection rate values for
almost all the CPGx tests analyzed. For instance, if providers
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A

B

FIGURE 1 | (A) The total number of genes selected by pharmacogenomics (PGx) tests as detailed by the test information included in the Genetic Testing Registry
(GTR). (B) Most commonly selected genes by PGx tests based on gene selection information included in GTR.

seeking to test patients of East Asian descent for CYP2C9
metabolizing status utilized any one of the CPGx tests, the
patients metabolizing status would likely be mischaracterized.
Additionally, our results show a large variance in PGx test
performance, meaning clinicians basing decisions on current
test results could be depending on incorrectly characterized
phenotypes. The greatest example of this variance was observed
with respect to the Oceanian (Oc) population and CYP2D6.
While average detection rate was greater than 80% for CPGx
tests, there were multiple tests with detection rates between
Frontiers in Genetics | www.frontiersin.org

30 and 40%. If clinicians are aware of the limitations of selective
CPGx tests with respect to different ethnic groups and their
variability, they can select an alternative; thus, patients will
be less likely to experience sub-optimal therapeutic outcomes.
Evaluation of AMP recommended Tier 1 and Tier 2 alleles
showed consistent detection rates of 90% or higher across
ethnic groups with a few notable exceptions. Specifically, East
Asian and SSA populations had significantly lower detection
rates for Tier 1 and 2 recommendations for CYP2C9 and
CYP2C19, respectively. In these cases, there are a significantly
5
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FIGURE 2 | The prevalence of altered metabolizing phenotypes of cytochrome P450 (CYP) enzymes across various ethnic groups. Abbreviations for ethnic groups
are as follows: AAAC, African American/Afro-Caribbean; Amer, American; CSA, Central/South Asian; EA, East Asian; Eur, European; Lat, Latino; NE, Near Eastern;
Oc, Oceanian; and SSA, Sub-Saharan African. *Values of 0 are due to the lack of variant frequencies documented in the Pharmacogenomics Knowledge Base
(PharmGKB) database for a specific ethnic group.

higher number of relevant gene variants compared to the other
populations. Despite these exceptions, it was concluded that
the results produced support the implementation of standardized
gene targets for targeted PGx tests.
Our results demonstrate additional measures that can be taken
to further increase the clinical utility of CPGx guided medication
therapy. For three out of the five CYP enzyme genes evaluated,
peak detection rates were achieved with different CPGx tests
depending on ethnic background because of gene selection
variations (Supplementary Table 8). Additionally, while higher
detection rates were often achieved by tests selecting a higher
number of variants, tests selecting fewer variants achieved the
same detection rate in many instances. This is due to the fact
that low frequency variants contribute minimally to the overall
detection rates. These results show providers considering ethnic
background in CPGx test selection can ensure their patients’
have the best chance to have their phenotypes correctly identified.
Physicians and pharmacists can better identify situations when
more selective tests are sufficient and when broader coverage
is needed. Careful consideration of CPGx test selection with
respect to ethnicity and variant selection has the potential to
improve patient care by better charactering altered metabolizing
phenotypes. With the growing emphasis on personalized patient
care, our results show meaningful ways to further individualize
genetic testing and ultimately improve outcomes.
Our results also provide insight into how the clinical utility
of informatics approaches can be enhanced. The findings of this
study can be potentially implemented in operationalizing PGx
test ordering, data sharing, and cascade testing with an integrative
Frontiers in Genetics | www.frontiersin.org

informatics approach (Roosan et al., 2021). We demonstrated
altered metabolizers are very prevalent in diverse patient
populations, and some ethnic populations have a significantly
higher proportion of altered metabolizers. This gene variance
implies some ethnic populations may be more likely to benefit
from the CPGx test. This is consistent with recent data from
PGx gene frequency studies in large diverse populations (McInnes
et al., 2021). If the patient ethnic background was included in
models predicting patients in need of PGx testing, it could
improve the models’ performance. Studies have demonstrated
ethnicity can be a predictive factor in disease progression and
medication efficacy with respect to various cardiovascular diseases
and more effective interventions can be initiated when it is
considered (Taylor and Wright, 2005). Besides, incorporating
ethnic background into the choice of CPGx test can assure
more reliable PGx results. Patients in need of PGx tests with
expanded gene coverage can be identified, ensuring metabolizing
status is assessed correctly. Thus, incorporating factors of ethnicity
and ethnicity in informatics tools can improve patient selection
for PGx testing and PGx test choice.
This study chose to evaluate CPGx tests due to the emerging
evidence showing they are needed to optimize clinical outcomes.
Studies comparing CPGx testing against single-gene testing to
guide medication decisions for patients with major depressive
disorder demonstrated that combinatorial approaches better
predicted phenotypes and clinical outcomes than single-gene
tests (Winner and Dechairo, 2015). Additionally, CPGx testing
approaches provide better opportunities for preemptive PGx
practice. In a sample of 10,000 patients preemptively genotyped
6
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(Goodman and Brett, 2021). Additionally, concerns have been
expressed regarding medical decision tools incorporating ethnicity
having bias that causes sub-optimal therapeutic outcomes for
patients of different ethnic backgrounds (Vyas et al., 2020).
However, the FDA and current PGx consortiums have adopted
ethnicity-based recommendations for PGx screenings (Chang
et al., 2020). This practice has been adopted as a common practice
with respect to other disease states. For example, ties between
familial genetic history and breast cancer risk have been well
documented and this information has been included in decisionmaking guidelines to screen patients as well (Owens et al., 2019).
Until universal PGx testing is widespread, using genetic ancestry
can prioritize patients most likely to benefit from a more appropriate
CPGx test representing known genetic variations.
There are several limitations to this study. With respect to
the availability of data, our evaluation only included voluntarily
shared commercial clinical laboratory data, which totaled 14
CPGx tests, 24% of total tests found. This is comparable to
an evaluation done on direct-to-consumer genetic tests in 2017,
which found only 20% of tests reporting gene selection data
(Hall et al., 2017). Therefore, our evaluation is biased by only
voluntarily shared data. Gene frequency information is only
sufficiently studied/reported in PharmGKB to perform our
analysis on CYP enzymes, even though, there are several other
genes commonly used in PGx practice.
Including all variants within PharmGKB regardless of their
function or frequency in our analysis also has its limitations.
For instance, CYP2D6 has nearly 150 variants identified with
less than half of them having reported gene frequencies or known
metabolic function. While a test may report a very low gene
coverage percentage, it may include several common clinically
relevant genes to achieve high detection rate. Sound gene selection
practices would be reflected in higher detection rate for that
test in a specific ethnic population. We considered all known
variants reported, rare or frequent, in calculating detection rate.
However, detection rates were not considerably influenced by
rare variants with unknown or very low frequencies. Diplotype
combinations occurring at very low frequencies relative to other
genes contribute very little to the total altered metabolizer
phenotype frequency in a population. Coverage percentages
indicate the extent of known variants included in an assay, while
detection rates indicate how well an assay captures the overall
diversity of the gene variants in a population. Therefore, both
gene coverage percentage and detection rate together provide
useful insight into gene variant selection practices for CPGx tests.
Our results highlight the prevalence of false-negative test results
when common gene variants are not included in CPGx tests.
Recent evaluations of the performance of sequencing technologies
utilized in CPGx tests demonstrate they have precision and
accuracy values greater than 99.9% (Jablonski et al., 2018). While
labs are required to meet standards of analytical performance,
they are not evaluated based on the genes they select. Thus,
high analytical performance measures can lead to a false sense
of security for consumers and providers if relevant genes are
not included in the assay. Conflict with respect to false negative
test results has come forward with respect to direct-to-consumer
genetic tests and breast cancer screenings. Many of the home

A

B

C

D

FIGURE 3 | Heatmaps displaying detection rate values and coverage
percentage of PGx tests covering (A) CYP2C9, (B) CYP2D6, (C) CYP2C19,
and (D) CYP2B6. The brighter the red, the higher the detection rate. On the
contrary, the darker blue, the lower the detection rate. In addition to the PGx
tests, detection rate was calculated for selected Tier 1 and Tier 2 alleles of
Association for Molecular Pathology (AMP) recommendations for CYP2C9
and CYP2C19. PGx test coverage percentage is included with each heatmap
as a bar chart on the right side of each heatmap. Abbreviations for ethnic
groups listed on the bottom of the figure are as follows: Amer, American;
CSA, Central/South Asian; EA, East Asian; Eur, European; Lat, Latino; NE,
Near Eastern; Oc, Oceanian; and SSA, Sub-Saharan African.

within the PREDICT program with Vanderbilt University, 91%
had at least one actionable variant, and 42% of these patients
had been exposed to a risk-associated medication in the past
(Hockings et al., 2020). Given the growing body of evidence
supporting the clinical benefits of CPGx testing, it is necessary
to evaluate these assays.
Utilizing reported racial and ethnic backgrounds in
healthcare decision-making is challenging for a variety of reasons.
A recent study suggests that ethnicity-based PGx decision-making
is limited by intrapopulation genetic variation and fluidity
Frontiers in Genetics | www.frontiersin.org
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testing kits incorporate BRCA variants specific to AshkenaziJewish descent, while not including other variants more common
in diverse populations leading to false negatives (Landi, 2019).
Our data show that this oversight leads to potential false negative
results in CPGx tests used in pharmacogenomics practice as well.
These false-negatives may significantly impact treatment decisions
for patients. Our work supports the continued implementation
of institutions like AMP creating recommended genes to include
in assays as a standard to ensure reliable results. However, the
landscape needs to be continually evaluated as gene frequency
and gene functionality information becomes more readily available.
In summary, the proportions of altered metabolizers in a
given population can range from 10 to 90% depending on
the CYP enzyme sub-class. The majority of assays targeted
less than 50% of known gene variants listed in the PharmGKB
gene frequency tables. Calculated detection rates of CPGx tests
showed high variation across different ethnic groups. Therefore,
the patient’s ethnicity receiving the PGx test and the variants
targeted by the test should be carefully considered to ensure
the optimal utility of PGx.

and accession number(s) can be found in the article/
Supplementary Material. All analysis codes are available at
https://github.com/sayer108/CPGx_test_evaluation.
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